title: Differential clinical profile of candesartan compared to other angiotensin receptor blockers.
abstract: The advantages of blood pressure (BP) control on the risks of heart failure and stroke are well established. The renin-angiotensin system plays an important role in volume homeostasis and BP regulation and is a target for several groups of antihypertensive drugs. Angiotensin II receptor blockers represent a major class of antihypertensive compounds. Candesartan cilexetil is an angiotensin II type 1 (AT[1]) receptor antagonist (angiotensin receptor blocker [ARB]) that inhibits the actions of angiotensin II on the renin-angiotensin-aldosterone system. Oral candesartan 8-32 mg once daily is recommended for the treatment of adult patients with hypertension. Clinical trials have demonstrated that candesartan cilexetil is an effective agent in reducing the risk of cardiovascular mortality, stroke, heart failure, arterial stiffness, renal failure, retinopathy, and migraine in different populations of adult patients including patients with coexisting type 2 diabetes, metabolic syndrome, or kidney impairment. Clinical evidence confirmed that candesartan cilexetil provides better antihypertensive efficacy than losartan and is at least as effective as telmisartan and valsartan. Candesartan cilexetil, one of the current market leaders in BP treatment, is a highly selective compound with high potency, a long duration of action, and a tolerability profile similar to placebo. The most important and recent data from clinical trials regarding candesartan cilexetil will be reviewed in this article.
authors.affiliation: The Brunner Institute for Cardiovascular Research, Wolfson Medical Center and Tel Aviv University, Tel Aviv, Israel.
authors.forename: Relu
authors.initials: R
authors.lastname: Cernes
authors.forename: Margarita
authors.initials: M
authors.lastname: Mashavi
authors.forename: Reuven
authors.initials: R
authors.lastname: Zimlichman
mesh_terms: D000419:Albuminuria; D047228:Angiotensin II Type 1 Receptor Blockers / Q000494:pharmacology / Q000627:therapeutic use*; D001158:Arteries / Q000503:physiopathology; D001562:Benzimidazoles / Q000494:pharmacology / Q000627:therapeutic use*; D001713:Biphenyl Compounds / Q000494:pharmacology / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D002318:Cardiovascular Diseases / Q000188:drug therapy / Q000517:prevention & control; D002986:Clinical Trials as Topic; D003404:Creatinine / Q000032:analysis; D003920:Diabetes Mellitus / Q000453:epidemiology / Q000517:prevention & control; D003930:Diabetic Retinopathy / Q000188:drug therapy; D018450:Disease Progression; D004548:Elasticity / Q000502:physiology; D006801:Humans; D016030:Kidney Transplantation; D015201:Meta-Analysis as Topic; D008881:Migraine Disorders / Q000188:drug therapy; D011507:Proteinuria; D013318:Stroke Volume; D013777:Tetrazoles / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D047228:Angiotensin II Type 1 Receptor Blockers; D001562:Benzimidazoles; D001713:Biphenyl Compounds; D013777:Tetrazoles; D003404:Creatinine; C077793:candesartan cilexetil